LV12309B - VACCINE CONTAINING Pneumococcal Polysaccharides - Google Patents

VACCINE CONTAINING Pneumococcal Polysaccharides Download PDF

Info

Publication number: LV12309B
Authority: LV; Latvia
Prior art keywords: ompc; polysaccharide; conjugate; miep; vvas
Prior art date: 1991-01-28

Application number

LVP-99-69A

Other languages

English (en)

Latvian (lv)

Other versions

LV12309A (lv

Inventor

Peter J. Kniskern

Charlotte C. Ip

Arpi Hagopian

John P. Hennessey Jr.

William J. Miller

Dennis J. Kubek

Pamela D. BURKE

Stephen Marburg

Richard L. Tolman

Original Assignee

Merck & Co., Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-28

Filing date

1999-04-26

Publication date

1999-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27094961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12309(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-04-26 Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.

1999-07-20 Publication of LV12309A publication Critical patent/LV12309A/xx

1999-11-20 Publication of LV12309B publication Critical patent/LV12309B/en

Links

239000005017 polysaccharide Substances 0.000 title claims abstract description 204
229920001282 polysaccharide Polymers 0.000 title claims abstract description 196
150000004676 glycans Chemical class 0.000 title claims abstract description 30
108010060123 Conjugate Vaccines Proteins 0.000 title description 10
229940031670 conjugate vaccine Drugs 0.000 title description 10
108090000623 proteins and genes Proteins 0.000 claims abstract description 131
102000004169 proteins and genes Human genes 0.000 claims abstract description 123
238000000034 method Methods 0.000 claims abstract description 118
239000000203 mixture Substances 0.000 claims abstract description 52
238000006460 hydrolysis reaction Methods 0.000 claims abstract description 47
230000007062 hydrolysis Effects 0.000 claims abstract description 44
230000008569 process Effects 0.000 claims abstract description 41
229960005486 vaccine Drugs 0.000 claims abstract description 35
230000002163 immunogen Effects 0.000 claims abstract description 26
230000000890 antigenic effect Effects 0.000 claims abstract description 19
241000193998 Streptococcus pneumoniae Species 0.000 claims abstract description 13
229940031000 streptococcus pneumoniae Drugs 0.000 claims abstract description 13
241000588650 Neisseria meningitidis Species 0.000 claims abstract description 9
230000036961 partial effect Effects 0.000 claims abstract description 9
208000035109 Pneumococcal Infections Diseases 0.000 claims abstract description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 159
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
230000021615 conjugation Effects 0.000 claims description 34
238000004458 analytical method Methods 0.000 claims description 26
150000001413 amino acids Chemical class 0.000 claims description 22
239000001488 sodium phosphate Substances 0.000 claims description 22
229910000162 sodium phosphate Inorganic materials 0.000 claims description 22
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 22
238000005194 fractionation Methods 0.000 claims description 20
125000006850 spacer group Chemical group 0.000 claims description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
238000011109 contamination Methods 0.000 claims description 14
239000000463 material Substances 0.000 claims description 14
238000004587 chromatography analysis Methods 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 11
101710116435 Outer membrane protein Proteins 0.000 claims description 10
239000012535 impurity Substances 0.000 claims description 10
239000000427 antigen Substances 0.000 claims description 9
102000036639 antigens Human genes 0.000 claims description 9
108091007433 antigens Proteins 0.000 claims description 9
230000001268 conjugating effect Effects 0.000 claims description 9
239000011780 sodium chloride Substances 0.000 claims description 9
230000000269 nucleophilic effect Effects 0.000 claims description 8
229940037003 alum Drugs 0.000 claims description 6
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 5
125000000524 functional group Chemical group 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
125000000129 anionic group Chemical group 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
238000010438 heat treatment Methods 0.000 claims description 4
238000003776 cleavage reaction Methods 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
230000007423 decrease Effects 0.000 claims description 3
230000003053 immunization Effects 0.000 claims description 3
230000000951 immunodiffusion Effects 0.000 claims description 3
230000001717 pathogenic effect Effects 0.000 claims description 3
230000007017 scission Effects 0.000 claims description 3
241000606768 Haemophilus influenzae Species 0.000 claims description 2
206010019786 Hepatitis non-A non-B Diseases 0.000 claims description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229940047650 haemophilus influenzae Drugs 0.000 claims description 2
230000003381 solubilizing effect Effects 0.000 claims description 2
238000001179 sorption measurement Methods 0.000 claims description 2
238000002604 ultrasonography Methods 0.000 claims 2
229940124718 AIDS vaccine Drugs 0.000 claims 1
206010011224 Cough Diseases 0.000 claims 1
206010039587 Scarlet Fever Diseases 0.000 claims 1
241001607520 Streptococcus pneumoniae 23F Species 0.000 claims 1
206010013023 diphtheria Diseases 0.000 claims 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims 1
229960002520 hepatitis vaccine Drugs 0.000 claims 1
229940124724 hepatitis-A vaccine Drugs 0.000 claims 1
229940124736 hepatitis-B vaccine Drugs 0.000 claims 1
229940041323 measles vaccine Drugs 0.000 claims 1
229940095293 mumps vaccine Drugs 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
229960001539 poliomyelitis vaccine Drugs 0.000 claims 1
239000000843 powder Substances 0.000 claims 1
229960002766 tetanus vaccines Drugs 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 71
239000000047 product Substances 0.000 abstract description 41
238000006243 chemical reaction Methods 0.000 abstract description 35
210000001744 T-lymphocyte Anatomy 0.000 abstract description 13
230000000694 effects Effects 0.000 abstract description 13
230000003497 anti-pneumococcal effect Effects 0.000 abstract description 9
150000001875 compounds Chemical class 0.000 abstract description 6
238000002955 isolation Methods 0.000 abstract description 5
241000124008 Mammalia Species 0.000 abstract description 4
210000003719 b-lymphocyte Anatomy 0.000 abstract description 4
239000013067 intermediate product Substances 0.000 abstract description 3
239000012528 membrane Substances 0.000 abstract description 3
230000002265 prevention Effects 0.000 abstract description 3
230000001939 inductive effect Effects 0.000 abstract description 2
101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 abstract 2
108010001267 Protein Subunits Proteins 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
238000003971 tillage Methods 0.000 abstract 1
150000004804 polysaccharides Chemical class 0.000 description 159
239000000243 solution Substances 0.000 description 143
239000000562 conjugate Substances 0.000 description 128
239000000523 sample Substances 0.000 description 93
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
229910001868 water Inorganic materials 0.000 description 72
235000018102 proteins Nutrition 0.000 description 70
239000000872 buffer Substances 0.000 description 55
238000007792 addition Methods 0.000 description 39
238000003556 assay Methods 0.000 description 36
108020004414 DNA Proteins 0.000 description 31
229940076788 pyruvate Drugs 0.000 description 30
239000000499 gel Substances 0.000 description 29
239000008188 pellet Substances 0.000 description 29
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 26
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 25
238000003756 stirring Methods 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 22
229940024606 amino acid Drugs 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 21
239000006228 supernatant Substances 0.000 description 21
238000000502 dialysis Methods 0.000 description 20
230000002829 reductive effect Effects 0.000 description 20
239000000126 substance Substances 0.000 description 20
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 19
239000012530 fluid Substances 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
239000000543 intermediate Substances 0.000 description 18
239000012064 sodium phosphate buffer Substances 0.000 description 18
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 18
239000013598 vector Substances 0.000 description 18
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 17
239000000306 component Substances 0.000 description 17
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 15
241000588653 Neisseria Species 0.000 description 15
239000012634 fragment Substances 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
238000005119 centrifugation Methods 0.000 description 14
229920001467 poly(styrenesulfonates) Polymers 0.000 description 14
229960003339 sodium phosphate Drugs 0.000 description 14
235000011008 sodium phosphates Nutrition 0.000 description 14
238000004848 nephelometry Methods 0.000 description 13
239000002244 precipitate Substances 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
238000001514 detection method Methods 0.000 description 12
229960001484 edetic acid Drugs 0.000 description 12
239000002609 medium Substances 0.000 description 12
-1 methyl pentose Chemical class 0.000 description 12
240000004808 Saccharomyces cerevisiae Species 0.000 description 11
239000011324 bead Substances 0.000 description 11
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 11
230000007935 neutral effect Effects 0.000 description 11
239000008363 phosphate buffer Substances 0.000 description 11
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
229910002092 carbon dioxide Inorganic materials 0.000 description 10
230000028993 immune response Effects 0.000 description 10
238000003127 radioimmunoassay Methods 0.000 description 10
238000011084 recovery Methods 0.000 description 10
239000011347 resin Substances 0.000 description 10
229920005989 resin Polymers 0.000 description 10
230000004044 response Effects 0.000 description 10
239000001632 sodium acetate Substances 0.000 description 10
235000017281 sodium acetate Nutrition 0.000 description 10
238000011282 treatment Methods 0.000 description 10
HMZKKJDOCRYTTH-UHFFFAOYSA-N 2-(2-aminoethylsulfanyl)acetic acid Chemical compound NCCSCC(O)=O HMZKKJDOCRYTTH-UHFFFAOYSA-N 0.000 description 9
241000282693 Cercopithecidae Species 0.000 description 9
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 9
238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 9
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
238000000855 fermentation Methods 0.000 description 9
230000004151 fermentation Effects 0.000 description 9
239000012467 final product Substances 0.000 description 9
238000011534 incubation Methods 0.000 description 9
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 9
150000002772 monosaccharides Chemical class 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
238000005549 size reduction Methods 0.000 description 9
125000003396 thiol group Chemical group [H]S* 0.000 description 9
238000006177 thiolation reaction Methods 0.000 description 9
AXFZADXWLMXITO-UHFFFAOYSA-N N-acetylcysteamine Chemical compound CC(=O)NCCS AXFZADXWLMXITO-UHFFFAOYSA-N 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
230000005875 antibody response Effects 0.000 description 8
238000010828 elution Methods 0.000 description 8
238000009472 formulation Methods 0.000 description 8
229930182830 galactose Natural products 0.000 description 8
230000001900 immune effect Effects 0.000 description 8
229920003023 plastic Polymers 0.000 description 8
239000004033 plastic Substances 0.000 description 8
238000003752 polymerase chain reaction Methods 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
239000004472 Lysine Substances 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 7
239000001569 carbon dioxide Substances 0.000 description 7
229960004424 carbon dioxide Drugs 0.000 description 7
238000004108 freeze drying Methods 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
239000011521 glass Substances 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
238000005259 measurement Methods 0.000 description 7
238000011027 product recovery Methods 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
238000005199 ultracentrifugation Methods 0.000 description 7
HVNXGOPARVAZNX-UHFFFAOYSA-N (4-nitrophenyl) 2-bromoacetate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)CBr)C=C1 HVNXGOPARVAZNX-UHFFFAOYSA-N 0.000 description 6
229920001817 Agar Polymers 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 6
NRFJZTXWLKPZAV-UHFFFAOYSA-N N-(2-oxo-3-thiolanyl)acetamide Chemical compound CC(=O)NC1CCSC1=O NRFJZTXWLKPZAV-UHFFFAOYSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
239000008272 agar Substances 0.000 description 6
239000001273 butane Substances 0.000 description 6
QVYARBLCAHCSFJ-UHFFFAOYSA-N butane-1,1-diamine Chemical group CCCC(N)N QVYARBLCAHCSFJ-UHFFFAOYSA-N 0.000 description 6
150000001720 carbohydrates Chemical class 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
229960001231 choline Drugs 0.000 description 6
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 6
229960004753 citiolone Drugs 0.000 description 6
238000010276 construction Methods 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
230000003301 hydrolyzing effect Effects 0.000 description 6
238000011068 loading method Methods 0.000 description 6
244000052769 pathogen Species 0.000 description 6
239000012071 phase Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000000376 reactant Substances 0.000 description 6
230000000405 serological effect Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 6
238000012546 transfer Methods 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
102000012410 DNA Ligases Human genes 0.000 description 5
108010061982 DNA Ligases Proteins 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
206010061598 Immunodeficiency Diseases 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 5
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
239000008121 dextrose Substances 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
210000003918 fraction a Anatomy 0.000 description 5
239000008103 glucose Substances 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
230000014759 maintenance of location Effects 0.000 description 5
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
230000000704 physical effect Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000001542 size-exclusion chromatography Methods 0.000 description 5
238000000527 sonication Methods 0.000 description 5
238000009283 thermal hydrolysis Methods 0.000 description 5
BWLMCOKQHQOEEE-BYPYZUCNSA-N (2s)-2-amino-4-(carboxymethylsulfanyl)butanoic acid Chemical compound OC(=O)[C@@H](N)CCSCC(O)=O BWLMCOKQHQOEEE-BYPYZUCNSA-N 0.000 description 4
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 4
241000283707 Capra Species 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000004793 Polystyrene Substances 0.000 description 4
241000473945 Theria <moth genus> Species 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
230000004520 agglutination Effects 0.000 description 4
230000032683 aging Effects 0.000 description 4
238000005571 anion exchange chromatography Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
XXWCODXIQWIHQN-UHFFFAOYSA-N butane-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NCCCCN XXWCODXIQWIHQN-UHFFFAOYSA-N 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000007872 degassing Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
210000002196 fr. b Anatomy 0.000 description 4
238000007306 functionalization reaction Methods 0.000 description 4
230000005484 gravity Effects 0.000 description 4
239000000413 hydrolysate Substances 0.000 description 4
238000001802 infusion Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000002054 inoculum Substances 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
239000000178 monomer Substances 0.000 description 4
229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000011218 seed culture Methods 0.000 description 4
238000010008 shearing Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000007858 starting material Substances 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
150000003573 thiols Chemical class 0.000 description 4
IFHAMTJNLDFVPU-LURJTMIESA-N (2s)-2-acetamido-4-(carboxymethylsulfanyl)butanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCSCC(O)=O IFHAMTJNLDFVPU-LURJTMIESA-N 0.000 description 3
MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
201000009906 Meningitis Diseases 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
206010043376 Tetanus Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
238000006640 acetylation reaction Methods 0.000 description 3
238000005903 acid hydrolysis reaction Methods 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000013019 agitation Methods 0.000 description 3
229940024545 aluminum hydroxide Drugs 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 3
229940041514 candida albicans extract Drugs 0.000 description 3
235000011089 carbon dioxide Nutrition 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000000470 constituent Substances 0.000 description 3
239000000356 contaminant Substances 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000835 fiber Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000006872 improvement Effects 0.000 description 3
229960003151 mercaptamine Drugs 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
229940031348 multivalent vaccine Drugs 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
239000012038 nucleophile Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229940049548 pneumovax Drugs 0.000 description 3
239000013587 production medium Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000004513 sizing Methods 0.000 description 3
235000020183 skimmed milk Nutrition 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
NGDIAZZSCVVCEW-UHFFFAOYSA-M sodium;butyl sulfate Chemical compound [Na+].CCCCOS([O-])(=O)=O NGDIAZZSCVVCEW-UHFFFAOYSA-M 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
239000011800 void material Substances 0.000 description 3
238000001262 western blot Methods 0.000 description 3
239000012138 yeast extract Substances 0.000 description 3
FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
FAYOCELKCDKZCA-UHFFFAOYSA-N 5-hydroxy-2,4-dimethylthiophen-3-one Chemical compound CC1SC(O)=C(C)C1=O FAYOCELKCDKZCA-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
244000202285 Acrocomia mexicana Species 0.000 description 2
235000003625 Acrocomia mexicana Nutrition 0.000 description 2
102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010006458 Bronchitis chronic Diseases 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
241000700114 Chinchillidae Species 0.000 description 2
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 2
101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 2
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
239000007993 MOPS buffer Substances 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
206010033078 Otitis media Diseases 0.000 description 2
201000005702 Pertussis Diseases 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
208000000474 Poliomyelitis Diseases 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical group CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
229960004308 acetylcysteine Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000009798 acute exacerbation Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940024546 aluminum hydroxide gel Drugs 0.000 description 2
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
239000012491 analyte Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
239000006161 blood agar Substances 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
208000007451 chronic bronchitis Diseases 0.000 description 2
238000007398 colorimetric assay Methods 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
238000003795 desorption Methods 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000011026 diafiltration Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000012039 electrophile Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
125000005179 haloacetyl group Chemical group 0.000 description 2
208000005252 hepatitis A Diseases 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
230000002998 immunogenetic effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
238000000464 low-speed centrifugation Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
238000005457 optimization Methods 0.000 description 2
238000005192 partition Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229940124733 pneumococcal vaccine Drugs 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
239000012492 regenerant Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
201000005404 rubella Diseases 0.000 description 2
238000007789 sealing Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
241000894007 species Species 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 description 2
238000004448 titration Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
239000002699 waste material Substances 0.000 description 2
LMDQWMLIAZQGLP-BYPYZUCNSA-N (2s)-2-[carboxy(methyl)amino]-4-sulfanylbutanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCS LMDQWMLIAZQGLP-BYPYZUCNSA-N 0.000 description 1
MSYWZRCJRHQKQK-UHFFFAOYSA-N (4-nitrophenyl) 6-[(2-bromoacetyl)amino]hexanoate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)CCCCCNC(=O)CBr)C=C1 MSYWZRCJRHQKQK-UHFFFAOYSA-N 0.000 description 1
YVTGUWMXPHFUQB-UHFFFAOYSA-N 1-azaniumylbutylazanium;dichloride Chemical compound Cl.Cl.CCCC(N)N YVTGUWMXPHFUQB-UHFFFAOYSA-N 0.000 description 1
GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical group NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
VKYZDCTWJGBFDW-UHFFFAOYSA-N 4-chloro-2-methylaniline;hydron;chloride Chemical compound Cl.CC1=CC(Cl)=CC=C1N VKYZDCTWJGBFDW-UHFFFAOYSA-N 0.000 description 1
ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000486679 Antitype Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
238000009631 Broth culture Methods 0.000 description 1
229910014033 C-OH Inorganic materials 0.000 description 1
101150030235 CTC1 gene Proteins 0.000 description 1
241000700112 Chinchilla Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
206010009137 Chronic sinusitis Diseases 0.000 description 1
238000006873 Coates reaction Methods 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
229910014570 C—OH Inorganic materials 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
229940032024 DPT vaccine Drugs 0.000 description 1
RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
102100024637 Galectin-10 Human genes 0.000 description 1
101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
238000012369 In process control Methods 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
206010058780 Meningitis neonatal Diseases 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
XOCCAGJZGBCJME-IANFNVNHSA-N N-Acetyl-D-fucosamine Chemical compound C[C@H]1OC(O)[C@H](NC(C)=O)[C@@H](O)[C@H]1O XOCCAGJZGBCJME-IANFNVNHSA-N 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
101100168115 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-6 gene Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108700033496 Recombivax HB Proteins 0.000 description 1
229940124942 Recombivax HB Drugs 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
IOMLBTHPCVDRHM-UHFFFAOYSA-N [3-[(2,4-dimethylphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound CC1=CC(C)=CC=C1NC(=O)C1=CC2=CC=CC=C2C=C1OP(O)(O)=O IOMLBTHPCVDRHM-UHFFFAOYSA-N 0.000 description 1
229920001284 acidic polysaccharide Polymers 0.000 description 1
150000004805 acidic polysaccharides Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229940009859 aluminum phosphate Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
229910052925 anhydrite Inorganic materials 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
229920001586 anionic polysaccharide Polymers 0.000 description 1
150000004836 anionic polysaccharides Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
244000309466 calf Species 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229960000800 cetrimonium bromide Drugs 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
230000007073 chemical hydrolysis Effects 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
201000005547 chronic conjunctivitis Diseases 0.000 description 1
208000027157 chronic rhinosinusitis Diseases 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
229940001442 combination vaccine Drugs 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000000332 continued effect Effects 0.000 description 1
230000002844 continuous effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
238000012136 culture method Methods 0.000 description 1
229940076286 cupric acetate Drugs 0.000 description 1
OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
229940099500 cystamine Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
229940075894 denatured ethanol Drugs 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
125000004427 diamine group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000000959 ear middle Anatomy 0.000 description 1
239000012834 electrophilic reactant Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002367 endolytic effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229910001679 gibbsite Inorganic materials 0.000 description 1
229940097042 glucuronate Drugs 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
239000006415 heart infusion blood agar Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000002766 immunoenhancing effect Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010965 in-process control Methods 0.000 description 1
238000013339 in-process testing Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
WNGZQMKZVLWGOD-UHFFFAOYSA-N n-(4-aminobutyl)-2-bromoacetamide Chemical compound NCCCCNC(=O)CBr WNGZQMKZVLWGOD-UHFFFAOYSA-N 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
229940052778 neisseria meningitidis Drugs 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
208000005923 otitis media with effusion Diseases 0.000 description 1
238000002578 otoscopy Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
238000011020 pilot scale process Methods 0.000 description 1
NTBYIQWZAVDRHA-ARQDHWQXSA-N pneumosamine Chemical compound C[C@@H](O)[C@H](O)[C@H](O)[C@H](N)C=O NTBYIQWZAVDRHA-ARQDHWQXSA-N 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000032361 posttranscriptional gene silencing Effects 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
229940070376 protein Drugs 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
239000013643 reference control Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
239000012465 retentate Substances 0.000 description 1
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000002336 sorption--desorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000007669 thermal treatment Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
125000000101 thioether group Chemical group 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-O tributylazanium Chemical compound CCCC[NH+](CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-O 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
238000000196 viscometry Methods 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)

LVP-99-69A 1991-01-28 1999-04-26 VACCINE CONTAINING Pneumococcal Polysaccharides LV12309B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64657091A	1991-01-28	1991-01-28
US80794291A	1991-12-19	1991-12-19

Publications (2)

Publication Number	Publication Date
LV12309A LV12309A (lv)	1999-07-20
LV12309B true LV12309B (en)	1999-11-20

Family

ID=27094961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-99-69A LV12309B (en)	1991-01-28	1999-04-26	VACCINE CONTAINING Pneumococcal Polysaccharides

Country Status (23)

Country	Link
US (1)	US5623057A (de)
EP (1)	EP0497525B2 (de)
JP (1)	JPH0794472B2 (de)
KR (1)	KR100243958B1 (de)
CN (1)	CN1080124C (de)
AT (1)	ATE169825T1 (de)
AU (1)	AU651656B2 (de)
CA (1)	CA2059692C (de)
CZ (1)	CZ283284B6 (de)
DE (1)	DE69226668T3 (de)
DK (1)	DK0497525T4 (de)
ES (1)	ES2121820T5 (de)
FI (1)	FI107370B (de)
HU (1)	HU216101B (de)
IE (1)	IE920244A1 (de)
IL (5)	IL119962A (de)
LV (1)	LV12309B (de)
MX (1)	MX9200328A (de)
NO (1)	NO304117B1 (de)
NZ (1)	NZ241367A (de)
SI (1)	SI9210081B (de)
SK (1)	SK280659B6 (de)
YU (1)	YU49068B (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2059693C (en) *	1991-01-28	2003-08-19	Peter J. Kniskern	Polysaccharide antigens from streptococcus pneumoniae
US5445817A (en) *	1992-08-21	1995-08-29	The United States Of America As Represented By The Department Of Health And Human Services	Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5439808A (en) *	1993-07-23	1995-08-08	North American Vaccine, Inc.	Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5565204A (en) *	1994-08-24	1996-10-15	American Cyanamid Company	Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) *	1995-01-12	1997-10-28	Connaught Laboratories Limited	Immunogenic conjugate molecules
US5747287A (en) *	1995-04-28	1998-05-05	North American Vaccine, Inc.	Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5866132A (en) *	1995-06-07	1999-02-02	Alberta Research Council	Immunogenic oligosaccharide compositions
KR19990007777A (ko) *	1995-06-07	1999-01-25	듀크두플레시스	면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법
US5695768A (en) *	1995-06-07	1997-12-09	Alberta Research Council	Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US6410025B1 (en)	1996-02-14	2002-06-25	Merck & Co., Inc.	Polysaccharide precipitation process
SE9601158D0 (sv) *	1996-03-26	1996-03-26	Stefan Svenson	Method of producing immunogenic products and vaccines
US6207157B1 (en)	1996-04-23	2001-03-27	The United States Of America As Represented By The Department Of Health And Human Services	Conjugate vaccine for nontypeable Haemophilus influenzae
PT939647E (pt) *	1996-08-27	2002-04-29	Chiron Corp	Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
FR2763244B1 (fr) *	1997-05-14	2003-08-01	Pasteur Merieux Serums Vacc	Composition vaccinale multivalente a porteur mixte
AU740956B2 (en)	1997-07-21	2001-11-15	Baxter Healthcare Sa	Modified immunogenic pneumolysin compositions as vaccines
US6224880B1 (en)	1997-09-24	2001-05-01	Merck & Co., Inc.	Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6756361B1 (en)	1997-10-14	2004-06-29	Nabi	Enterococcus antigens and vaccines
GB9727262D0 (en) *	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
EP1053015A2 (de) *	1998-02-12	2000-11-22	American Cyanamid Company	Mit interleukin-12 formulierten pneumokokkus und meningokokkus impfstoffen
US7018637B2 (en) *	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999055715A2 (en) *	1998-04-28	1999-11-04	Galenica Pharmaceuticals, Inc.	Polysaccharide-antigen conjugates
GB9816337D0 (en) *	1998-07-27	1998-09-23	Cortecs Uk Ltd	Proteins
US9134303B1 (en)	1998-08-25	2015-09-15	Alere Scarborough, Inc.	ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en)	1998-09-18	2004-11-30	Binax, Inc.	Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20080096236A1 (en) *	1998-08-25	2008-04-24	Binax, Inc.	Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US6146902A (en) *	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
JP2002539273A (ja) *	1999-03-19	2002-11-19	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ワクチン
GB9906437D0 (en) *	1999-03-19	1999-05-12	Smithkline Beecham Biolog	Vaccine
US20040191834A1 (en) *	1999-10-28	2004-09-30	Laferriere Craig Antony Joseph	Novel method
DK1296715T4 (en) *	2000-06-29	2016-03-07	Smithkline Beecham Biolog	Multivalent vaccine composition.
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
EP1569955A2 (de) *	2002-12-03	2005-09-07	Sloan-Kettering Institute For Cancer Research	Gp120-spezifische-antigene, deren konjugate, verfahren zu ihrer herstellung und ihre anwendung
US7369578B2 (en) *	2003-07-01	2008-05-06	Nortel Networks Limited	Digital processing of SONET pointers
EP1699810A4 (de) *	2003-12-17	2009-10-21	Elan Pharm Inc	A beta-immunogene peptid-träger-konjugate und verfahren zu deren herstellung
UA93854C2 (ru) *	2003-12-17	2011-03-25	Вайет Ллк	Иммуногенный конъюгат и способ его получения
EP2298340B1 (de)	2004-09-22	2014-04-16	GlaxoSmithKline Biologicals S.A.	Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
US7955605B2 (en)	2005-04-08	2011-06-07	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en)	2005-04-08	2010-05-04	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) *	2005-04-08	2007-08-09	Wyeth	Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (de) *	2005-04-08	2012-03-07	Wyeth LLC	Multivalente Pneumokokken-Polysaccharidproteinkonjugatzusammensetzung
AU2011253684B8 (en) *	2005-04-08	2013-07-11	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
LT2351578T (lt)	2005-06-27	2017-04-10	Glaxosmithkline Biologicals S.A.	Vakcinų gavimo būdas
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
GB0607088D0 (en) *	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
BRPI0620460B8 (pt)	2005-12-22	2021-05-25	Glaxosmithkline Biologicals Sa	uso de composição imunogênica para bebês, e, processo para produzir uma vacina
CN101024079B (zh) *	2006-02-17	2012-02-01	福州昌晖生物工程有限公司	肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
MY148405A (en)	2006-03-30	2013-04-30	Glaxosmithkline Biolog Sa	Immunogenic composition
AU2013200552B9 (en) *	2006-04-07	2014-07-03	Glaxosmithkline Biologicals S.A.	Conjugate vaccines
TW200806315A (en)	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en)	2006-05-08	2014-08-19	Wyeth Llc	Pneumococcal dosing regimen
CN101553246B (zh) *	2006-08-07	2019-05-21	哈佛大学校长及研究员协会	蛋白质基质疫苗及这种疫苗的制备和给药方法
EA015964B1 (ru)	2006-09-07	2012-01-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
KR101467002B1 (ko) *	2006-10-10	2014-12-01	와이어쓰 엘엘씨	스트렙토코쿠스 뉴모니애 제3형 다당류의 정제 방법
CN1963500B (zh) *	2006-12-06	2010-05-12	云南沃森生物技术股份有限公司	一种肺炎链球菌荚膜多糖结合物中游离多糖含量的测定方法
GB0700136D0 (en)	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Process for manufacturing vaccines
DK2129693T3 (en) *	2007-03-23	2017-02-13	Wyeth Llc	BRIEF PURIFICATION PROCEDURE FOR THE PREPARATION OF STREPTOCOCCUS PNEUMONIAE-Capsule POLYACCHARIDES
EP2155244B1 (de)	2007-04-23	2017-03-22	Serum Institute of India Private Limited	Antigene polysaccharide und verfahren zu ihrer herstellung
EA201490303A1 (ru)	2007-05-02	2014-05-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
BRPI0813644B8 (pt)	2007-06-26	2021-05-25	Glaxosmithkline Biologicals Sa	composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
WO2010042481A1 (en)	2008-10-06	2010-04-15	University Of Chicago	Compositions and methods related to bacterial eap, emp, and/or adsa proteins
DK2379734T3 (en) *	2008-12-18	2018-04-23	Wyeth Llc	Method for Controlling the Molecular Weight of Polysaccharide of Streptococcus Pneumoniae Serotype 19A
ES2749952T3 (es)	2008-12-18	2020-03-24	Wyeth Llc	Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
WO2010083477A2 (en)	2009-01-16	2010-07-22	University Of Maryland, Baltimore	Broad spectrum vaccine against non-typhoidal salmonella
EP3281947B1 (de)	2009-04-03	2020-02-12	The University of Chicago	Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten
WO2010141312A2 (en)	2009-06-01	2010-12-09	Wake Forest University Health Sciences	Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
CN107126557A (zh) *	2009-06-29	2017-09-05	健诺西生物科学公司	抗肺炎链球菌的疫苗和组合物
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003922D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Conjugation process
EP2555794A4 (de)	2010-04-05	2014-01-15	Univ Chicago	Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
WO2011148382A1 (en)	2010-05-28	2011-12-01	Biological E Limited	An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
ES2655701T3 (es)	2010-07-02	2018-02-21	The University Of Chicago	Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP5793194B2 (ja)	2010-09-09	2015-10-14	ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ	感染防御ブドウ球菌抗原が関与する方法および組成物
WO2012100234A1 (en)	2011-01-20	2012-07-26	Genocea Biosciences, Inc.	Vaccines and compositions against streptococcus pneumoniae
GB201103836D0 (en)	2011-03-07	2011-04-20	Glaxosmithkline Biolog Sa	Conjugation process
JP5944480B2 (ja)	2011-03-22	2016-07-05	セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド	多糖を調製するための新規な方法
US8945588B2 (en)	2011-05-06	2015-02-03	The University Of Chicago	Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
RS56709B1 (sr)	2011-12-06	2018-03-30	Valneva Austria Gmbh	Jedinjenja aluminijuma za primenu u terapeuticima i vakcinama
AU2013209513B2 (en)	2012-01-20	2017-10-05	Children's Medical Center Corporation	Fused antigen vaccines and compositions against Streptococcus pneumoniae
HRP20201127T1 (hr)	2012-04-26	2020-11-27	University Of Chicago	Antigeni stafilokokne koagulaze i metode primjene istih
ITMI20121597A1 (it) *	2012-09-25	2014-03-26	Beta Pharma S A	Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
CA2900008C (en)	2013-02-07	2025-10-07	Children's Medical Center Corporation	PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
RU2016103771A (ru) *	2013-07-07	2017-08-11	Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф.	Синтетические вакцины против streptococcus pneumoniae 1-го типа
WO2015095868A1 (en)	2013-12-20	2015-06-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
KR20210032013A (ko) *	2014-01-21	2021-03-23	화이자 인코포레이티드	스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
PT3096785T (pt) *	2014-01-21	2020-10-13	Pfizer	Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12616744B2 (en)	2014-01-21	2026-05-05	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA2939416A1 (en)	2014-02-14	2015-08-20	Pfizer Inc.	Immunogenic glycoprotein conjugates
US9815886B2 (en)	2014-10-28	2017-11-14	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
CA2988366C (en) *	2015-06-08	2021-12-07	Serum Institute Of India Private Ltd.	Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof.
WO2017117539A1 (en)	2015-12-30	2017-07-06	Northwestern University	Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
EP3436061A4 (de)	2016-03-31	2019-12-04	Liffey Biotech Limited	Saccharid-polypeptidkonjugat-zusammensetzungen und verfahren zur verwendung davon
US11191822B2 (en)	2016-06-22	2021-12-07	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Pneumococcal polysaccharide-protein conjugate composition
EP3269385A1 (de)	2016-07-12	2018-01-17	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
US10829795B2 (en)	2016-07-14	2020-11-10	Northwestern University	Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
US11951165B2 (en)	2016-12-30	2024-04-09	Vaxcyte, Inc.	Conjugated vaccine carrier proteins
MX2019007910A (es)	2016-12-30	2019-12-05	Sutrovax Inc	Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US20200222550A1 (en) *	2017-01-31	2020-07-16	Merck Sharp & Dohme Corp.	Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR20240169144A (ko)	2017-01-31	2024-12-02	머크 샤프 앤드 돔 엘엘씨	다당류-단백질 접합체 제조 방법
WO2018144799A1 (en)	2017-02-03	2018-08-09	SCHADECK, Eva, Barbara	Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
KR102701633B1 (ko)	2017-02-24	2024-09-02	머크 샤프 앤드 돔 엘엘씨	폐렴구균 접합체 백신 제제
WO2018156467A1 (en) *	2017-02-24	2018-08-30	Merck Sharp & Dohme Corp.	Methods for improving filterability of polysaccharide-protein conjugate reactions
US11400162B2 (en)	2017-02-24	2022-08-02	Merck Sharp & Dohme Llc	Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en)	2017-06-10	2020-08-04	Inventprise, Llc	Mixtures of polysaccharide-protein pegylated compounds
KR20240018698A (ko)	2017-06-10	2024-02-13	인벤트프라이즈 인크.	면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US11389540B2 (en)	2017-09-07	2022-07-19	Merck Sharp & Dohme Llc	Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
BR112020004509A8 (pt)	2017-09-07	2023-01-31	Merck Sharp & Dohme	Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
US11524076B2 (en)	2017-09-07	2022-12-13	Merck Sharp & Dohme Llc	Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074706A1 (en)	2017-09-07	2019-03-14	Merck Sharp & Dohme Corp.	Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050813A1 (en)	2017-09-07	2019-03-14	Merck Sharp & Dohme Corp.	ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
AU2018328040B2 (en)	2017-09-07	2025-01-16	Merck Sharp & Dohme Llc	Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
EP3691677A4 (de)	2017-10-04	2021-07-07	Pogona, Llc	Saccharid-polypeptidkonjugat-zusammensetzungen und verfahren zur verwendung davon
BR112020011414B8 (pt)	2017-12-06	2023-01-31	Merck Sharp & Dohme	Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
CN108079286B (zh) *	2018-01-19	2020-07-31	云南沃森生物技术股份有限公司	一种13价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
US11530432B2 (en)	2018-03-19	2022-12-20	Northwestern University	Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
EP3897705A2 (de)	2018-12-19	2021-10-27	Merck Sharp & Dohme Corp.	Zusammensetzungen mit polysaccharidproteinkonjugaten von streptococcus pneumoniae und verfahren zu deren verwendung
WO2020146814A1 (en)	2019-01-11	2020-07-16	Northwestern University	Bioconjugate vaccines' synthesis in prokaryotic cell lysates
WO2020229964A1 (en)	2019-05-10	2020-11-19	Glaxosmithkline Biologicals Sa	Conjugate production
US12226410B2 (en)	2019-10-18	2025-02-18	Northwestern University	Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
AU2020371793A1 (en)	2019-10-25	2022-06-02	Northwestern University	Cell-free extract preparation protocol for enrichment of membrane vesicles and increased glycoprotein yields
BR112022008761A2 (pt)	2019-11-22	2022-07-26	Glaxosmithkline Biologicals Sa	Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
WO2021173632A1 (en) *	2020-02-25	2021-09-02	Merck Sharp & Dohme Corp.	Methods for monitoring the progress of polysaccharide size-reduction
EP3900739A1 (de)	2020-04-21	2021-10-27	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de)	2020-06-02	2021-12-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
US20230250142A1 (en)	2020-06-12	2023-08-10	Glaxosmithkline Biologicals Sa	Dock tag system
EP4192499A4 (de)	2020-08-10	2024-09-25	Inventprise, Inc.	Multivalente pneumokokken-glykokonjugat-impfstoffe, die nachkommende serotyp 24f enthalten
TW202245835A (zh)	2021-02-04	2022-12-01	美商默沙東有限責任公司	用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
EP4297776A1 (de)	2021-02-26	2024-01-03	Biological E Limited	Aktiviert-gelöschtes polysaccharid und verbesserte verfahren zur quantifizierung des polysaccharids in einer impfstoffzusammensetzung
EP4169513A1 (de)	2021-10-19	2023-04-26	GlaxoSmithKline Biologicals S.A.	Hilfsstoffzusammensetzung enthaltend sting agonisten
CA3267399A1 (en)	2022-09-19	2024-03-28	Biological E Limited	PROCESS FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES
GEAP202616883A (en)	2023-05-18	2026-03-25	Merck Sharp & Dohme Llc	Compounds and adjuvant formulations useful in pneumococcal vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4324887A (en) *	1978-08-16	1982-04-13	President And Fellows Of Harvard College	Type II group B Streptococci polysaccharide
US4221906A (en) *	1979-03-19	1980-09-09	American Cyanamid Company	Stabilization of pneumococcal polysaccharides
US4242501A (en) *	1979-08-08	1980-12-30	American Cyanamid Company	Purification of pneumococcal capsular polysaccharides
US4271147A (en) *	1980-01-10	1981-06-02	Behringwerke Aktiengesellschaft	Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
IE51174B1 (en) *	1980-04-14	1986-10-29	Merck & Co Inc	Group b streptococcal capsular polysaccharides
FR2495939B1 (fr) *	1980-12-11	1985-10-11	Merieux Inst	Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
NL8202527A (nl) *	1982-06-22	1984-01-16	Univ Utrecht	Vaccins tegen door bacterien met kapsel-polysacchariden verwekte ziekten en werkwijze voor het bereiden daarvan.
US4496538A (en) *	1982-07-06	1985-01-29	Connaught Laboratories, Inc.	Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) *	1982-07-06	1987-02-17	Connaught Laboratories, Inc.	Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4619828A (en) *	1982-07-06	1986-10-28	Connaught Laboratories, Inc.	Polysaccharide exotoxoid conjugate vaccines
US4459286A (en) *	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine
US4686102A (en) *	1984-04-12	1987-08-11	American Cyanamid Company	Multivalent pneumococcal vaccine and preparation thereof
US4882317A (en) *	1984-05-10	1989-11-21	Merck & Co., Inc.	Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) *	1984-05-10	1987-09-22	Merck & Co., Inc.	Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) *	1984-12-20	1990-02-26	Merck & Co Inc	Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
IT1187753B (it) *	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
US4707543A (en) *	1985-09-17	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4727136A (en) *	1985-10-01	1988-02-23	Canadian Patents And Development Ltd.	Modified meningococcal group B polysaccharide for conjugate vaccine
ES2000034A6 (es) *	1985-11-26	1987-10-01	Schweiz Serum & Impfinst	Procedimiento para la preparacion de una vacuna viva contra paperas
US4755381A (en) *	1986-03-27	1988-07-05	Swiss Serum And Vaccine Institute Berne	Klebsiella capsular polysaccharide vaccine
EP0302887B1 (de) *	1986-04-16	1994-06-22	The Brigham And Women's Hospital, Inc.	Bakterielle antigene, antikörper, impfstoffe und deren herstellung
NZ223009A (en) *	1986-12-31	1990-06-26	Nl Rivm Of Thoven	Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
ES2051909T3 (es) *	1988-04-19	1994-07-01	American Cyanamid Co	Vacuna del conjugado de polisacarido-proteina de membrana externa contra la haemophilus influenzae tipo b.
US5091300A (en) *	1989-08-03	1992-02-25	Merck & Co., Inc.	Radio-immuno assay for hepatitis b virus pres2 antibodies
CA2059693C (en) *	1991-01-28	2003-08-19	Peter J. Kniskern	Polysaccharide antigens from streptococcus pneumoniae
JP2636128B2 (ja) *	1993-02-03	1997-07-30	株式会社アマダメトレックス	パンチング金型

1992
- 1992-01-20 CA CA002059692A patent/CA2059692C/en not_active Expired - Lifetime
- 1992-01-21 IL IL11996292A patent/IL119962A/xx not_active IP Right Cessation
- 1992-01-21 IL IL10071692A patent/IL100716A/en not_active IP Right Cessation
- 1992-01-21 IL IL11996192A patent/IL119961A/xx not_active IP Right Cessation
- 1992-01-22 NZ NZ241367A patent/NZ241367A/en not_active IP Right Cessation
- 1992-01-23 SK SK199-92A patent/SK280659B6/sk not_active IP Right Cessation
- 1992-01-23 CZ CS92199A patent/CZ283284B6/cs not_active IP Right Cessation
- 1992-01-24 AU AU10467/92A patent/AU651656B2/en not_active Expired
- 1992-01-27 SI SI9210081A patent/SI9210081B/sl unknown
- 1992-01-27 CN CN92100700A patent/CN1080124C/zh not_active Expired - Lifetime
- 1992-01-27 DK DK92300655.5T patent/DK0497525T4/da active
- 1992-01-27 MX MX9200328A patent/MX9200328A/es unknown
- 1992-01-27 FI FI920353A patent/FI107370B/fi active
- 1992-01-27 YU YU8192A patent/YU49068B/sh unknown
- 1992-01-27 KR KR1019920001108A patent/KR100243958B1/ko not_active Expired - Lifetime
- 1992-01-27 DE DE69226668T patent/DE69226668T3/de not_active Expired - Lifetime
- 1992-01-27 EP EP92300655A patent/EP0497525B2/de not_active Expired - Lifetime
- 1992-01-27 HU HUP9200252A patent/HU216101B/hu unknown
- 1992-01-27 ES ES92300655T patent/ES2121820T5/es not_active Expired - Lifetime
- 1992-01-27 IE IE024492A patent/IE920244A1/en unknown
- 1992-01-27 NO NO920350A patent/NO304117B1/no not_active IP Right Cessation
- 1992-01-27 AT AT92300655T patent/ATE169825T1/de not_active IP Right Cessation
- 1992-01-28 JP JP4012941A patent/JPH0794472B2/ja not_active Expired - Lifetime
1994
- 1994-05-20 US US08/246,394 patent/US5623057A/en not_active Expired - Lifetime
1997
- 1997-01-03 IL IL11996297A patent/IL119962A0/xx unknown
- 1997-01-03 IL IL11996197A patent/IL119961A0/xx unknown
1999
- 1999-04-26 LV LVP-99-69A patent/LV12309B/en unknown

Also Published As

Publication number	Publication date
FI107370B (fi)	2001-07-31
JPH0565300A (ja)	1993-03-19
US5623057A (en)	1997-04-22
DE69226668T3 (de)	2010-12-16
EP0497525A3 (en)	1993-03-10
NO920350L (no)	1992-07-29
SI9210081B (en)	2001-12-31
JPH0794472B2 (ja)	1995-10-11
LV12309A (lv)	1999-07-20
KR100243958B1 (ko)	2000-02-01
CA2059692C (en)	2004-11-16
HU9200252D0 (en)	1992-04-28
EP0497525B1 (de)	1998-08-19
YU8192A (sh)	1994-12-28
DE69226668D1 (de)	1998-09-24
IE920244A1 (en)	1992-07-29
MX9200328A (es)	1992-09-01
HU216101B (hu)	1999-04-28
CA2059692A1 (en)	1992-07-29
ATE169825T1 (de)	1998-09-15
DK0497525T4 (da)	2010-07-05
DE69226668T2 (de)	1999-04-22
ES2121820T3 (es)	1998-12-16
SI9210081A (en)	1996-02-29
HUT69968A (en)	1995-09-28
IL119962A0 (en)	1997-04-15
IL100716A (en)	1999-12-22
FI920353A0 (fi)	1992-01-27
SK280659B6 (sk)	2000-05-16
NZ241367A (en)	1994-04-27
AU651656B2 (en)	1994-07-28
AU1046792A (en)	1992-07-30
IL119961A0 (en)	1997-04-15
ES2121820T5 (es)	2010-05-28
CN1064217A (zh)	1992-09-09
NO304117B1 (no)	1998-10-26
IL119961A (en)	2000-01-31
NO920350D0 (no)	1992-01-27
EP0497525A2 (de)	1992-08-05
KR920014829A (ko)	1992-08-25
IL100716A0 (en)	1992-09-06
DK0497525T3 (da)	1998-10-26
CZ283284B6 (cs)	1998-02-18
IL119962A (en)	2000-01-31
EP0497525B2 (de)	2010-03-03
FI920353L (fi)	1992-07-29
CN1080124C (zh)	2002-03-06
YU49068B (sh)	2003-08-29
CS19992A3 (en)	1992-10-14

Publication	Publication Date	Title
US5623057A (en)	1997-04-22	Pneumococcal polysaccharide conjugate vaccine
EP0497524B1 (de)	1998-07-15	Polysaccharidantigene aus Streptococcus pneumoniae
US4830852A (en)	1989-05-16	Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins and methods of preparing such polysaccharides and conjugates
US4695624A (en)	1987-09-22	Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en)	1989-11-21	Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5371197A (en)	1994-12-06	Protein-dimeric polysaccharide conjugate vaccine
WO2014027302A1 (en)	2014-02-20	Glycoconjugation processes and compositions
JP7630603B2 (ja)	2025-02-17	出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
CN107961369A (zh)	2018-04-27	多价脑膜炎球菌缀合疫苗及其制备方法
JP2024153605A (ja)	2024-10-29	多糖－タンパク質結合体の吸着を改善する方法及びその方法により得られる多価ワクチン製剤